bromovinyldeoxyuridine
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2007 (NCT00550004)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
ORF36 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1/C=C/Br- Mol. weight
- 333.14 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL31634 ↗
Also known as
- 5-(2-bromoethenyl)-2'-deoxyuridine
- 5-(2-bromovinyl)-2'-deoxyuridine
- 5-bvdu
- berlin-chemie brand of brivudine
- brivudin
- brivudin
- brivudine
- brivudine
- brivudine
- brivudine
- brivudine
- brivudine
- brivudine
- bromovinyldeoxyuridine
- bromovinyldeoxyuridine
- bromovinyldeoxyuridine
- bvdu
- bvdu
- bvdu
- (e)-5-(2-bromovinyl)-2'-deoxyuridine
- e-5-(2-bromovinyl)-durd
- rp101
- rp101
- rp101
- uridine, 5-(2-bromoethenyl)-2'-deoxy-, (e)-
- (z)-5-(2-bromovinyl)-2'-deoxyuridine
- z-5-(2-bromovinyl)-durd
- zostex
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00550004 | Phase 2 | Sep 1, 2007 | SciClone Pharmaceuticals |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SciClone Pharmaceuticals | For profit | 1 | 1 | 1 | 2007 |
1 organizations
Page 1 / 1